19+114! The National Medical Insurance and Commercial Insurance 'Dual Catalog' Released: Success Rate of Innovative Drug Negotiations Increases to 88%

China's National Healthcare Security Administration added 114 drugs to the 2025 national medical insurance catalogue (50 Class I innovative drugs) with an 88% negotiation success rate (up from 76% in 2024) and will implement the list from Jan 1, 2026; 19 drugs were included in the inaugural commercial insurance innovative drug directory, notably five CAR-T therapies. The NHSA said medical insurance funds spent roughly RMB 13 trillion during the 14th Five‑Year Plan and over RMB 460 billion on negotiated drugs during agreement periods; policy measures include a six‑month transition for delisted items, provincial procurement listing by end‑Dec 2025 and hospital P&T adjustments by end‑Feb 2026. Key beneficiaries named include Hengrui’s PCSK9 inhibitor Recaticimab and Kelun’s ADC Lurofucanatumab (H1 sales >RMB300m), and the inclusion—plus 'three exclusions' support for commercial directory drugs—is likely to accelerate market access and revenue growth for innovative and rare‑disease drug makers but will require monitoring of regional implementation details.

Analysis

Market structure: The insurance inclusions structurally reallocate demand toward China-origin innovators (Hengrui 600276.SH, Kelun 06990.HK, JW 02126.HK, CARsgen 02171.HK) and commercial-insurance-friendly specialties (CAR‑T, orphan drugs, long‑acting PCSK9). Short‑term winners are manufacturers of newly listed drugs and Chinese commercial insurers that can sell tailored riders; losers include incumbent high‑priced suppliers in China (Amgen’s Evolocumab as a targeted share loss) and exporters competing on price. Pricing power will compress for products forced to list at or below reimbursement caps, while differentiated delivery (e.g., 8‑week dosing) can capture share despite price constraints.

Risk assessment: Key tail risks include regional non‑implementation (provincial listing deadline Dec 31, 2025), retroactive price interventions, or tighter reimbursement ceilings that erode gross margins (>20–40% downside to modeled peak sales). Immediate (days) reactions will be sentiment; short‑term (weeks–months) depends on provincial procurement and hospital P&T decisions (deadline Feb 28, 2026); long‑term (2–4 years) is market share migration and negotiated price resets. Hidden dependency: volume ramp requires hospital adoption, cold‑chain/infusion capacity and insurer product design — absent those, uptake lags despite catalog inclusion.

Key Decisions for Investors

• Establish a 1.5–3.0% long position in TAK (Takeda) over 9–12 months via equity or a 9‑month call spread 25–40% OTM to capture upside if commercial insurance products accelerate uptake post-inclusion; reduce cost basis with a bear put spread if downside exceeds 20% from entry.
• Allocate 2.0–3.0% long to China domestic winners (e.g., Hengrui 600276.SH, Kelun 06990.HK, JW 02126.HK, CARsgen 02171.HK) evenly across names; hedge 0.5–1.0% by shorting AMGN to express expected PCSK9 share erosion in China over 12–24 months.
• Enter a pair trade: long 2% JW Therapeutics (02126.HK) or CARsgen (02171.HK) vs short 1% Gilead/other imported ADC exposure in China for 12–18 months, sizing to limit portfolio delta to <1%; close if provincial listings are not completed by Dec 31, 2025 or P&T inclusion by Feb 28, 2026.
• Overweight Chinese commercial health insurers by +2% relative to benchmark, tactically from Jan–Jun 2026, to profit from new product sales; trim if claims run 30% above modeled levels or regulators introduce broader 'three exclusions' reversals.
• Monitor three hard catalysts before scaling above tactical sizes: provincial centralized procurement listings by 31‑Dec‑2025, hospital P&T adoption by 28‑Feb‑2026, and any national guidance tightening reimbursement caps within the next 90 days — act (add/reduce 50% position) within one week of each trigger.